Monopar files for $40M IPO to test chemo side effect drug

Nasdaq
Monopar Therapeutics is planning an adaptive trial to mitigate risks related to shaky phase 2 data. (Nasdaq)

Monopar Therapeutics has filed to raise $40 million through an IPO. The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

Illinois-based Monopar licensed the severe oral mucositis treatment, clonidine mucoadhesive buccal tablet Validive, from Onxeo for $1 million upfront in 2017. The deal came two years after the drug failed to drive a statistically significant reduction in incidence of severe oral mucositis in phase 2. 

Onxeo zeroed in on “observed differences in the incidence and time to occurrence” of the side effect to justify its conclusion that further development was warranted. Monopar agreed with the conclusion, leading to a heavily backloaded deal.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Now, Monopar wants investors to put up the cash to enable it to put its belief to the test. The money will equip Monopar to start a phase 3 trial before the end of 2019. Monopar plans to run an adaptive design trial that enables it to perform an interim analysis about 12 months after the study begins. A confirmatory second trial will get underway shortly after the interim analysis.

The design reflects the limitations of the midphase data generated by Onxeo. Monopar thinks the phase 2 missed its primary endpoint because of the “relatively small sample size” but acknowledges the failure “increases the risk of the phase 3 trials.” The adaptive trial is designed to mitigate the risk.

“Our adaptive design approach will allow us to confirm or reject our hypothesis based off the phase 2 data that the optimal patient population for Validive is likely either all [oropharyngeal cancer] (OPC) patients or HPV+ OPC patients, and then run a confirmatory second trial should it be warranted,” Monopar wrote in its IPO filing.

Monopar thinks the IPO funding will see it through to the interim review and potentially into the start of the confirmatory second study. If the interim data are positive, Monopar will have partly derisked the asset and will be in a stronger position to raise money for the rest of the study.

Suggested Articles

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics has added another $110 million to its coffers.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.